Oct. 25 at 5:47 AM
$CADL Recent studies confirm that the presence of mature TLS correlates with better survival in solid tumors (e.g. melanoma, NSCLC, lung), and their assembly is a "bottleneck" for antitumor immunity. Positioning the TLS inductor as a "TME reprogrammer" is right: it transforms a hostile environment into a pro-inflammatory one, potentially saving that 70% of patients who do not respond to ICI.
• Multimodal innovation with HSV-1 oncolytic virus: Using a programmable HSV-1 is brilliant, because it exploits the selective lysis of cancer cells to release antigens and stimulate innate immunity (via PAMPs and DAMPs). The AI touch with enLIGHTEN™ to design multi-gene payloads that recapitulate the 4-phase cascade (probably: initial recruitment, stromal organization, DC/T trigger, B/HEV maturation) exceeds the limits of single agonists such as LIGHT or LTBR.
